伏立康唑医院给药与监测审计及剂量预测软件性能评估
该研究回顾性审计澳大利亚某公立医院2016年伏立康唑治疗,评估给药与治疗药物监测(TDM)对澳大利亚国家指南的依从性,并评价一款商业剂量预测软件中一室群体药代动力学模型的预测性能。结果显示给药依从性差,仅27%血浆浓度为谷浓度,其中57%在治疗范围;剂量预测软件偏差和精度可接受。
要点
- 伏立康唑给药对指南依从性差,仅口服200mg剂量指南推荐时依从性较好。
- 仅27%血浆浓度为谷浓度,其中57%达治疗范围,37%低于治疗范围。
- 剂量预测软件预测性能可接受,偏差0.09 mg/L,精度1.32 (mg/L)²。
核心结论
- 基于已发表指南和TDM结果,伏立康唑给药欠佳。
- 剂量预测软件可增强TDM指导的治疗。
研究设计与样本
- 共纳入110个治疗疗程,其中41%为预防,59%为侵袭性真菌感染。
- 收集患者人口学、给药史和血浆浓度,评估与澳大利亚指南的一致性,并比较观察浓度与剂量预测软件预测浓度。
主要发现
- 给药指南依从性差,除非口服制剂指南推荐200 mg剂量,该剂量为最常见处方剂量(占56%处方)。
- 82%(90/110)疗程获得血浆伏立康唑浓度,每疗程中位3次(范围1-27)。
- 少数(27%)血浆浓度为谷浓度,中位浓度1.5 mg/L(范围<0.1至>5.0 mg/L)。
- 谷浓度中57%(58/101)为治疗范围,37%(37/101)低于治疗范围,6%(6/101)高于治疗范围。
- 剂量预测软件表现良好,偏差0.09 mg/L(95%CI -0.08至0.27),精度1.32 (mg/L)²(95%CI 0.96-1.67)。
关键数值与推荐
- 指南依从性评估基于澳大利亚国家指南。
- 谷浓度治疗范围未在原文中明确报告。
临床怎么用
- 伏立康唑治疗应遵循指南给药并加强TDM,尤其关注谷浓度监测。
- 剂量预测软件可作为辅助工具优化TDM指导的个体化给药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic drug monitoring (TDM) is recommended to guide voriconazole therapy. OBJECTIVES: To determine compliance of hospital-based voriconazole dosing and TDM with the Australian national guidelines and evaluate the predictive performance of a one-compartment population pharmacokinetic voriconazole model available in a commercial dose-prediction software package. METHODS: A retrospective audit of voriconazole therapy at an Australian public hospital (1 January to 31 December 2016) was undertaken. Data collected included patient demographics, dosing history and plasma concentrations. Concordance of dosing and TDM with Australian guidelines was assessed. Observed concentrations were compared with those predicted by dose-prediction software. Measures of bias (mean prediction error) and precision (mean squared prediction error) were calculated. RESULTS: Adherence to dosing guidelines for 110 courses of therapy (41% for prophylaxis and 59% for invasive fungal infections) was poor, unless oral formulation guidelines recommended a 200 mg dose, the most commonly prescribed dose (56% of prescriptions). Plasma voriconazole concentrations were obtained for 82% (90/110) of courses [median of 3 (range: 1-27) obtained per course]. A minority (27%) of plasma concentrations were trough concentrations [median concentration: 1.5 mg/L (range: <0.1 to >5.0 mg/L)]. Of trough concentrations, 57% (58/101) were therapeutic, 37% (37/101) were subtherapeutic and 6% (6/101) were supratherapeutic. The dose-prediction software performed well, with acceptable bias and precision of 0.09 mg/L (95% CI -0.08 to 0.27) and 1.32 (mg/L)2 (95% CI 0.96-1.67), respectively. CONCLUSIONS: Voriconazole dosing was suboptimal based on published guidelines and TDM results. Dose-prediction software could enhance TDM-guided therapy.
引用
- Chaudhri K, Stocker SL, Williams KM, et al. Voriconazole: an audit of hospital-based dosing and monitoring and evaluation of the predictive performance of a dose-prediction software package. J Antimicrob Chemother. 2020. PMID: 32277819. doi:10.1093/jac/dkaa098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。